Check Out Dr. Sharon Malone in the Washington Post!

This year marks twenty years since the National Institutes of Health terminated research on the effects of hormone therapy on menopausal women. Alloy’s Chief Medical Officer, Dr. Sharon Malone, wrote an Op-Ed in the Washington Post along with Jennifer Weiss-Wolf talking about the decision to stop research and the effect it’s had on menopause treatment for millions of women in the years since.

“More than 1 billion people worldwide will be in menopause by 2025,” she says. Today, there are 55 million people in menopause in the United States alone, and nearly 75 percent of them are not being treated. And, these aren’t minor aches and pains we’re talking about. Hot flashes, anxiety, depression, brain fog, frequent UTIs, and sleeplessness can be debilitating. If you’ve been around Alloy enough, you know these are only a few of the 34 symptoms of menopause that can totally upend our lives after we turn 40.

The piece calls on the medical establishment to give menopause the respect it deserves. Menopausal Hormone Therapy is safe–the American College of Obstetricians and Gynecologists, American Association of Clinical Endocrinologists, and North American Menopause Society (plus many, many other medical societies) all agree. Equally important, it works. The NIH needs to redesign and launch a new comprehensive reproductive-health initiative. We need to be informed of the long-term benefits of Menopausal Hormone Therapy, as well as given an accurate assessment of any risks. The FDA also should remove its “black box warning” from estrogen-only products. The risks are overstated, according to Weiss-Wolf and Dr. Malone, and the warnings outdated.

We deserve better. You deserve better. Alloy is proud to offer evidence-based, science-backed treatments and to have experts like Dr. Malone on our team. Head over to the Washington Post for the full article.